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BACKGROUND AND PURPOSE
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased risk for stroke, heart failure
and cardiovascular-related mortality. Candidate targets for anti-AF drugs include a potassium channel Kv1.5, and the ionic
currents IKACh and late INa, along with increased oxidative stress and activation of NFAT-mediated gene transcription. As
pharmacological management of AF is currently suboptimal, we have designed and characterized a multifunctional small
molecule, compound 1 (C1), to target these ion channels and pathways.
EXPERIMENTAL APPROACH
We made whole-cell patch-clamp recordings of recombinant ion channels, human atrial IKur, rat atrial IKACh, cellular recordings
of contractility and calcium transient measurements in tsA201 cells, human atrial samples and rat myocytes. We also used a
model of inducible AF in dogs.
KEY RESULTS
C1 inhibited human peak and late Kv1.5 currents, frequency-dependently, with IC50 of 0.36 and 0.11 μmol·L−1 respectively. C1
inhibited IKACh (IC50 of 1.9 μmol·L−1) and the Nav1.5 sodium channel current (IC50s of 3 and 1 μmol·L−1 for peak and late
components respectively). C1 (1 μmol·L−1) significantly delayed contractile and calcium dysfunction in rat ventricular myocytes
treated with 3 nmol·L−1 sea anemone toxin (ATX-II). C1 weakly inhibited the hERG channel and maintained antioxidant and
NFAT-inhibitory properties comparable to the parent molecule, resveratrol. In a model of inducible AF in conscious dogs, C1
(1 mg·kg−1) reduced the average and total AF duration.
CONCLUSION AND IMPLICATIONS
C1 behaved as a promising multifunctional small molecule targeting a number of key pathways involved in AF.
Abbreviations
AERP, atrial effective refractory period; AF, atrial fibrillation; BCL, basic cycle length; CABG, coronary artery bypass
graft surgery; C1, compound 1; DPPH, diphenylpicrylhydrazyl; NRVM, neonatal rat ventricular myocytes
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Introduction
Atrial fibrillation (AF) is the most common type of cardiac
arrhythmia and the incidence of AF is increasing with an
ageing population (Naccarelli et al., 2009; McManus et al.,
2012). While AF does not generally induce sudden cardiac
death, AF increases the risk of stroke fivefold (Wolf et al.,
1991; Hart and Halperin, 2001; McManus et al., 2012), can
cause tachycardia-induced cardiomyopathy (Nerheim et al.,
2004) and adverse electrical and structural remodelling of the
heart (Franz et al., 1997; Anter et al., 2009). Furthermore,
∼30% of patients undergoing coronary artery bypass graft
(CABG) surgery develop transient post-operative AF (Andrews
et al., 1991; Mathew et al., 2004). Current pharmacotherapy
of AF is still suboptimal because some of the drugs used for
rhythm control also display significant risk for acquired long
QT syndrome and Torsades des Pointes arrhythmias (Taira
et al., 2010) and may increase the incidence of vascular events
(Connolly et al., 2011). Therefore, there is a significant need
for the development of improved therapeutic agents for AF.
Over the past decade, studies on the cellular pathways in
AF have revealed potential therapeutic targets to develop new
anti-AF drugs. One important target is the ultra-rapid potas-
sium channel (IKur/Kv1.5; channel and receptor nomenclature
follows Alexander et al., 2013) preferentially expressed in the
atria, but not the ventricle (Wang et al., 1993; Gaborit et al.,
2007; Tamargo et al., 2009; Ravens and Wettwer, 2011). In
addition to Kv1.5 channel, IKACh (Ehrlich and Nattel, 2009),
voltage-gated sodium channels (Burashnikov et al., 2007;
Burashnikov and Antzelevitch, 2012), oxidative stress
(Carnes et al., 2001; Mihm et al., 2001) and activation of the
transcription factor NFAT (Lin et al., 2004) have all been
implicated in AF development. Given the complex aetiology
of AF, it has been suggested that drugs targeting multiple
pathways involved in AF development may be more effective
(Dobrev and Nattel, 2010; Dobrev et al., 2012). To date, AF
drugs have been exclusively targeted towards ion channels.
However, non-ionic remodelling events also likely contribute
to the initiation and maintenance of AF as well. It has been
further suggested that targeting maladaptive remodelling
events in AF may also be required for effective control of AF
(Burashnikov and Antzelevitch, 2011). Therefore, based on
these criteria, a multifunctional small-molecule drug for AF
should ideally possess the following properties: (i) frequency-
dependent Kv1.5 inhibition; (ii) IKACh inhibition; (iii) late
sodium current inhibition; (iv) lack of hERG channel inhibi-
tion; (v) display atrial specificity, that is, no effect on repo-
larization and excitation–contraction (EC) coupling in
ventricular tissue; (vi) antioxidant properties; (vii) NFAT inhi-
bition; and (viii) functional efficacy in a large-animal model
of inducible AF.
Resveratrol is a bioactive polyphenol found in red grape
products that has been investigated extensively for its cardio-
protective and anti-ageing properties (Brisdelli et al., 2009;
Dolinsky and Dyck, 2011). We have previously shown that
resveratrol (i) inhibits NFAT activation and hypertrophic
remodelling in cardiac tissue (Chan et al., 2008; Dolinsky
et al., 2009) and (ii) inhibits the late INa current preferentially
over peak current (Wallace et al., 2006). Based on these mul-
tifunctional properties, the aim of the present study was to
synthesize, using resveratrol as the parent molecule, a novel
small molecule called compound 1 (C1) and to characterize
its antioxidant, NFAT-inhibitory effects and electrophysi-
ological profile with respect to Kv1.5, IKACh, late INa and hERG.
We also determined its in vivo efficacy in a model of inducible
AF in dogs.
Methods
Chemical synthesis of compounds
Details of the chemical synthesis used to generate four
unique resveratrol hybrid bis-ortho-substituted biphenyl
diamide derivatives are provided in Supporting Information
Appendix S1.
Cell transfection
The human Nav1.5 and hERG clones were generously pro-
vided by Dr Arthur Brown (Case Western Reserve University,
USA) and Dr Henry Duff (University of Calgary, Canada)
respectively. Expression vectors were co-transfected into the
tsA201 cell line (Sigma Aldrich, St Louis, MO, USA) with a
GFP expression vector using the calcium phosphate precipi-
tation technique. TsA201 cells are a transformed HEK293 cell
line expressing the temperature-sensitive antigen to increase
expression levels of recombinant proteins. Transfected cells
were then used within 48 h. All in vitro experiments were
performed at room temperature (20–22°C).
Kv1.5 currents
Recordings were made from single tsA201 cells stably express-
ing the human heart Kv1.5 gene. Pipettes were pulled from
borosilicate glass capillary tubing (Warner Instruments,
Hamden, CT, USA) and tips were fire-polished, producing
resistances of 1–3 MΩ. The pipette solution contained (in
mmol·L−1): 140 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES and 10 EGTA.
The pH was adjusted to 7.3 with KOH. A concentration of
2 mmol·L−1 MgATP was added immediately before use. Cells
were bathed in extracellular solution contained (in
mmol·L−1): 135 NaCl, 5.4 KCl, 1 CaCl2, 1.2 MgCl2, 10 HEPES
and 5 glucose (pH adjusted to 7.4 with NaOH). Solutions were
applied to cells using a multi-input perfusion pipette (switch
time <2 s). Once a giga-seal was formed, the patch was rup-
tured and the whole-cell voltage-clamp technique was used
to record Kv1.5 currents. Currents were elicited by 120 ms
duration test pulses to +40 mV from a holding potential of
−100 mV with a cycle length of 0.3, 1 or 3 Hz respectively.
Data were acquired using an Axopatch 200B patch-clamp
amplifier and Clampex 8.2 software (Axon Instruments,
Foster City, CA, USA).
Nav1.5 currents
Single tsA201 cells transfected with mammalian expression
vectors encoding the human heart Nav1.5 channel were used
for recording of whole-cell Nav1.5 currents, as described pre-
viously (Wallace et al., 2006). Voltage steps from a holding
potential of −120–40 mV every 10 mV was used to generate
the current–voltage (I –V) relationship for peak INa.
hERG currents
tsA201 cells were transfected with a mammalian expression
vector encoding the hERG channel clone (Kv11.2) as
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described for Nav1.5 channels above and hERG currents were
recorded as described previously (Kikuchi et al., 2005).
Human atrial IKur currents
For experiments on human atrial IKur (Kv1.5) atrial tissue was
collected from 7 male patients aged 40-75 years undergoing
CABG surgery at the University Hospital, University of
Alberta, Canada. We obtained prior ethical approval from the
University of Alberta human ethics board and informed
patient consent. The atrial appendage samples were collected
during surgery and enzymically dissociated into single atrial
myocytes as described below. Human atrial appendage
samples were cut into small pieces and washed 3 times for
10 min with 10ml of a calcium-free Tyrode’s solution in a
shaking water bath at 32oC. The sample was enzymically
digested for 45 min in 10 ml of Tyrode’s solution containing
20 mg Type II collagenase (Worthington, Lakewood NJ, USA)
and 4 mg protease type XIV (Sigma Aldrich) in a shaking
water bath at 32oC. After 45 min the supernatant is removed
and 10 ml solution containing 20 mg Type II collagenase
only was added and the sample further digested for 10 min at
32oC. Isolated cells are removed in the supernatant, centri-
fuged and resuspended in Tyrode’s solution. IKur currents were
then measured using a modification of the whole-cell record-
ing protocol to inactivate Ito currents, as described previously
(Cai et al., 2007).
Animals
All animal care and experimental procedures involving adult
and neonatal rats complied with the guidelines of the Cana-
dian Council for Animal Care and the project was approved
by the University of Alberta research ethics office. All studies
involving animals are reported in accordance with the
ARRIVE guidelines for reporting experiments involving
animals (Kilkenny et al., 2010; McGrath et al., 2010). A total
of 15 adult rats, 69 neonatal rats and 5 dogs were used in the
experiments described here.
Rat atrial IKACh and recombinant IK1 currents
Rat atrial myocytes were isolated as described previously
(Komukai et al., 2002) from 15 adult male Sprague-Dawley
rats (150-200 g) obtained from the animal facility at Biologi-
cal Sciences, University of Alberta. Whole-cell recordings of
carbachol-induced IKACh currents were made using the same
solutions used for Kv1.5 and a voltage step protocol from
−110 to +50 mV with a holding potential of −80 mV. IK1
whole-cell currents were measured in tsA201 cells transiently
transfected with the KIR2.1 clone using the same solutions
and voltage protocols used for IKACh currents.
Cell shortening and calcium
transient recordings
These were measured in rat ventricular myocytes prepared
from adult Sprague-Dawley rats killed by an overdose of
pentobarbital (150 mg kg−1, i.p.). The hearts were removed
and right ventricular myocytes were then obtained by
enzymic dissociation using standard protocols, which have
been described previously (Bouchard et al. 1993; Light et al.
1998). Cell shortening and calcium transients were measured
using standard procedures previously published by our labo-
ratory (Baczko et al., 2005; Wallace et al., 2006).
NFAT reporter assay
Neonatal rat ventricular myocytes (NRVM) were isolated
from the hearts of 1-3-day-old neonatal rat pups and cultured
in DMEM/F-12, containing 5% fetal bovine serum, 10%
horse serum, 50 μg ml−1 gentamicin, and 1% penicillin-
streptomycin for 16h, as described previously (Kovacic et al.
2003). 24h prior to the initiation of experiments, the medium
was changed to serum-free DMEM/F-12 containing 50 μg ml−1
gentamicin supplemented with 1× insulin, transferrin,
sodium selenite (ITS)+3 liquid media supplement (Chan et al.,
2008). All subsequent treatments of the myocytes were per-
formed in this serum-free medium for either 1 or 24 h. NRVM
were infected with Ad.GFP or Ad.NFAT-Luc-Promoter adeno-
virus (Seven Hills Bioreagents, Cincinnati, OH, USA) at an
infection multiplicity of 10. Cells were treated 24 h post-
infection with vehicle or varying concentrations of C1 or
resveratrol and/or angiotensin II (1 μmol·L−1 for 24 h). Cells
were harvested with the reporter lysis buffer supplied in the
luciferase assay system kit (Promega, Madison, WI, USA) and
luminescence according to the manufacturer’s instructions.
Anti-oxidant assay
A diphenylpicrylhydrazyl (DPPH) assay (Pyrzynska and Pekal,
2013) was used to determine the antioxidant capacity of C1
and resveratrol. A ethanolic solution of H2O2 (200 nmol·L−1)
was mixed with DPPH alone, or DPPH with either resveratrol
or C1 at various concentrations. The final concentration of
ethanol in the experimental solution was 0.1%. The absorb-
ance of these solutions was measured at 517 nm, with a lower
absorbance representing an increase in antioxidant capacity.
Model of induced AF in vivo
All experiments were carried out in compliance with the
Guide for the Care and Use of Laboratory Animals (USA NIH
publication No 85–23, revised 1996) and approved by the
Department of Animal Health and Food Control of the
Ministry of Agriculture and Rural Development, Hungary
(XIII/01031/000/2008). Adult male Beagle dogs (age: 24-26
months, weight: 14–16 kg; supplied by the University of
Szeged Experimental Animal Facility, Hungary) were anaes-
thetized with ketamine (Richter Gedeon Ltd., Hungary;
induction: 10 mg kg−1, maintenance: 2 mg kg−1, every 20 min)
and xylazine (CP-Pharma Handelsges, Germany; induction:
1 mg kg−1, maintenance: 0.2 mg kg−1, every 20 min) and were
mechanically ventilated. The implantation procedure was
carried out under antibiotic coverage as follows: amoxicillin/
clavulanic acid (1000 mg/200 mg i.v.; Richter Gedeon Ltd.)
and gentamicin (40 mg i.v.; Sandoz GmbH, Kundl, Austria)
given before the operation, amoxicillin/clavulanic acid
(500 mg/125 mg orally, twice a day for 5 days; Augmentin
500mg/125mg®; GlaxoSmithKline Ltd., Hungary) given fol-
lowing the operation. For peri-operative analgesia metami-
zole sodium (1000 mg i.v., 1g/2ml; Sanofi-Aventis Hungary
Ltd., Hungary) and tramadol (50 mg i.v., TEVA Ltd., Hungary,
under licence from Grünenthal GmbH, Aachen, Germany)
were administered.
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The procedure involved the implantation of two bipolar
pacemaker electrodes (Synox SX 53-JBP® and Synox SX
60/15-BP®, Biotronik Hungary Ltd., Hungary) into the right
atrial appendage and apex of the right ventricle, the elec-
trodes were connected to pacemakers (Logos DS® and Philos
S®, Biotronik Hungary Ltd., Hungary) in subcutaneous
pockets in the neck area, radiofrequency catheter ablation of
the AV node was performed to avoid high atrial pacing rates
propagating into the ventricles. The ventricular pacemaker
was set between 80 to 90 beats/min, following the baseline
heart rate of the dog before the operation.
Following recovery from surgery (3 days), high frequency
right atrial pacing was started at 400 beats/min, maintained
for 6 to 7 weeks before the experiments to allow electrical
remodeling of the atria (monitored by the measurement of
the right atrial effective refractory period (AERP) every second
day). The AERPs were measured at basic cycle lengths (BCL) of
150 and 300 ms with a train of 10 stimuli (S1) followed by an
extrastimulus (S2), with the AERP defined as the longest S1S2
interval that did not produce a response. AERP shorter than
80 ms could not be measured in conscious animals (pace-
maker measurement limit). No animals were lost between
pacemaker, pacemaker electrode implantation and experi-
mental use.
On the day of the experiment atrial pacing was stopped,
continuous recording of the electrocardiogram commenced
using precordial leads and the AERP was measured. A control
set (25 times) of 10-second long rapid atrial bursts (800 beats/
min, at twice threshold) were performed in order to induce
atrial fibrillation in conscious dogs preceded by a bolus
infusion of vehicle (20 mL of a mixture of DMSO +
β-hydroxypropyl-cyclodextrin + saline (all from Sigma, St.
Louis, USA), DMSO concentration less than 0.1%, infused in
15 min). During the control 25 bursts and subsequent AF
episodes, a continuous infusion of vehicle was maintained (in
a volume of 1.7 mL/kg/min). Following the measurement of
AERP, Compound 1 (C1) was infused in a dose of 0.3 mg/kg
(in 15 min bolus + maintenance) and AF was again induced
25 times. An identical procedure was repeated in every dog
with 1 mg/kg dose of C1. The incidence of AF, the total
duration of AF, the average duration of AF episodes were
measured along with changes in atrial refractory period and
QT interval. QT intervals were measured on dogs with pace-
maker implantation before the 12th burst and were not cor-
rected for heart rate since QT measurements were made at
heart rate set to 80 beats/min by the ventricular pacemaker in
each animal. Experiments were done in freely moving con-
scious dogs so that any interference from anesthetics could be
ruled out.
HPLC assay of plasma levels of C1
Blood samples were collected from the vena cephalica from
the right foreleg for later determination of the plasma levels
of C1, before and after administration of C1 infusion at
designated time points. For each time point (5 min before the
administration of 0.3 mg/kg C1, 30 min after the administra-
tion of 0.3 and 1 mg/kg C1) 4 mL of blood was taken into
tubes containing lithium heparin. The tubes were immedi-
ately centrifuged at 4 oC for 15 min at 3000g and the sepa-
rated plasma was stored in a freezer at −20oC.
For each sample, 100 μL of plasma was combined with
100 μL of deionized water and the entire volume was loaded
into individual wells of a 96-well Isolute SLE+ (supported
liquid extraction) plate from Biotage (PN 820-00200-P01;
Charlotte, NC, USA). The samples were eluted into a 96-well
collection plate using 1 ml of tert-butyl methyl ether. The
solvent was completely evaporated using a TurboVap 96 and
samples were reconstituted in 200 μL of 0.1% formic acid in
a 50/50 water/acetonitrile mixture. Analysis was performed
using an Acquity UPLC-TQD (Waters) in multiple reaction
monitoring mode (positive electrospray).
Data analysis
Data are expressed as mean ± SEM. In whole animal experi-
ments, each animal served as its own control, after one-way
ANOVA, the groups were compared in pairs by means of Stu-
dent’s t-test. In cell-based experiments, one-way ANOVAs or
paired Student’s t-tests were used as appropriate. A level of
P < 0.05 was considered to be significant..
Materials
Angiotensin II, carbachol, DPPH, E-4031 and resveratrol were
obtained from Sigma Aldrich. The anemone toxin ATX II, was
obtained from Alomone Labs (Jerusalem, Israel).
Results
Effects of C1 on Kv1.5 currents
The inhibitory effects on Kv1.5 currents of four novel resvera-
trol derivatives (Figure 1A) were compared with those of the
parent molecule, resveratrol. Resveratrol is a weak inhibitor of
Kv1.5 currents (IC50 = 66 μmol·L−1; Figure 1B). Of the four
derivatives synthesized, C1 was found to be the most potent
Kv1.5 inhibitor (IC50s = 0.36 μmol·L−1 and 0.11 μmol·L−1 for
peak and late current inhibition, respectively; Figure 1B–E).
Compounds 2–4 displayed intermediate Kv1.5 peak current
inhibitory potencies of 8.3, 10.9 and 11.2 μmol·L−1 respec-
tively (Figure 1B). Therefore, only C1 was selected for further
characterization in this study.
Frequency-dependent effects of C1 on
Kv1.5 currents
The frequency-dependent effects of C1 were tested on whole-
cell Kv1.5 currents in the tsA201 cell line stably expressing
Kv1.5 channels. At 1 Hz, 0.3 μmol·L−1 C1 displayed a time-
dependent inhibition of Kv1.5 currents, reaching a steady-
state after 15 s (Itest/Icontrol = 0.74 ± 0.02). In contrast, at a
higher stimulation frequency of 3 Hz, the observed C1
inhibition was increased, reaching a steady-state level of
0.50 ± 0.03 when compared with control (n = 5 cells;
Figure 2A,B).
Effects of C1 on human atrial IKur currents
Single atrial myocytes were isolated from human atrial
appendage samples obtained during CABG surgery and
whole-cell IKur currents measured. Application of C1
(0.3 μmol·L−1) reversibly inhibited IKur to 31.0 ± 1.8% of
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control values (n = 3 cells; Figure 2C,D), a value similar to that
observed on recombinant Kv1.5 (Figures 1D and 2A,B).
Effects of C1 on rat atrial IKACh and
recombinant IK1 currents
Single atrial cells were isolated from rat hearts and IKACh cur-
rents were elicited by application of carbachol. C1 signifi-
cantly inhibited carbachol-induced rat atrial IKACh currents
with an IC50 of 1.9 μmol·L−1 (Figure 3). In contrast, 3 μmol·L−1
C1 had no significant inhibitory effect on recombinant IK1
(Kir2.1) whole-cell currents transiently expressed in tsA201
cells (see Supporting Information Appendix S1 for results).
Effects of C1 on human Nav1.5 currents
The effects of C1 were tested on peak and late recombinant
Nav1.5 whole-cell currents. Application of 3 μmol·L−1 C1
resulted in a 50% inhibition of peak current (Figure 4A,B). To
establish the concentration–response curves for peak and late
Nav1.5 currents, cells were treated with the sea anemone
toxin (ATX-II) (3 nmol·L−1) to induce the late-current compo-
nent and to test the inhibitory effects of C1 at differing
concentrations. C1 preferentially inhibits the late current
when compared with peak current (IC50s = 1.1 μmol·L−1 vs.
3.2 μmol·L−1, respectively; Figure 4C,D).
Effects of C1 on hERG currents
Inhibition of the hERG (IKr, Kv11.2) is highly undesirable and
may result in arrhythmogenic QT prolongation (Sanguinetti
et al., 1996; Sanguinetti and Tristani-Firouzi, 2006; Taira et al.,
2010). Therefore, we tested the effects of C1 on recombinant
whole-cell hERG channel currents. hERG currents were
positively identified by their characteristic inactivation at
positive holding potentials, large tail currents and inhi-
bition by 1 μmol·L−1 E-4031 (Figure 5A). Construction of
concentration–inhibition curves revealed that C1 is a weak
inhibitor of peak and tail hERG currents (Figure 5B,C), with
IC50s of 30 and 25 μmol·L−1, respectively, values that are
100-fold higher than those inhibiting peak and late Kv1.5
currents.
C1 antioxidant capacity and NFAT activation
Antioxidant therapy has been shown to reduce the incidence
of post-operative AF in humans (Carnes et al., 2001), and
reactive oxygen species (ROS) also directly activate Kv1.5
Figure 1
Effects of resveratrol and its derivatives on recombinant Kv1.5 current inhibition. (A) Chemical structures of resveratrol and the four resveratrol
derivatives, C1–C4. (B) Concentration–inhibition curves of the effect of resveratrol and the four resveratrol derivatives (C1–C4) on Kv1.5 peak
current amplitude (IC50s = 66.0, 0.36, 8.3, 10.9 and 11.2 μmol·L−1, respectively, n = 4–7 cells for each concentration). (C) Representative traces
before and after application of 0.3 μmol·L−1 C1. (D) Current–voltage curves of Kv1.5 peak and late currents before and after application of
0.3 μmol·L−1 C1 compared with control. *P<0.05, #P<0.01 significantly different from control values; paired Student’s t-test. (E) Concentration–
inhibition curves of the effect of C1 on peak and late Kv1.5 current compared with control (peak current IC50 = 0.36 μmol·L−1, late current
IC50 = 0.11 μmol·L−1, n = 4–6 cells for each concentration).
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channels (Caouette et al., 2003). As resveratrol is a known
antioxidant, we compared the antioxidant properties of C1
with resveratrol. At 10 μmol·L−1, resveratrol and C1 displayed
significant antioxidant capacities (0.59 ± 0.04 vs. 0.77 ± 0.02
of maximal DPPH 517 nm absorbance signal; Figure 6A). At
100 μmol·L−1, these values were 0.09 ± 0.02 and 0.19 ± 0.02
for resveratrol and C1 respectively.
We have previously shown that resveratrol inhibits NFAT
activation induced by phenylephrine contributing to a reduc-
tion in maladaptive hypertrophy in NRVMs (Chan et al.,
2008). Accordingly, we tested the effects of C1 on NFAT
activation in NRVMs. Treatment of NRVMs with 0.01–
25 μmol·L−1 of C1 resulted in a significant reduction in NFAT
activity when compared to no treatment (Figure 6B). These
experiments revealed that C1 significantly reduced NFAT
activity at concentrations of 0.1 μmol·L−1 and higher,
with 1 μmol·L−1 of C1 exhibiting half-maximal inhibition
(Figure 6B). As 1 μmol·L−1 of C1 inhibited NFAT activation by
50%, we used this concentration to determine whether C1
was able to inhibit NFAT activation in response to a pro-
hypertrophic stimuli. NRVMs were infected as above and
treated with vehicle, AngII (1 μmol·L−1), C1 (1 μmol·L−1) or
AngII + C1 (1 μmol·L−1) for 24 h. As expected, treatment of
NRVM with 1 μmol·L−1 of AngII significantly increased NFAT
Figure 2
Effects of C1 on human atrial IKur. (A) Representative traces of frequency-dependent effect on steady-state current by application of 0.3 μmol·L−1
C1 compared with controls (n = 5). Top: Effect on steady-state current at 1 Hz stimulation (Itest/Icontrol = 0.74 ± 0.02). Bottom: Effect at 3 Hz
stimulation (Itest/Icontrol = 0.50 ± 0.03). (B) Use-dependent effects of 0.3 μmol·L−1 C1 on IKur at 1 and 3 Hz stimulation. *P < 0.05, significantly
different from control values; paired Student’s t-test. (C) Representative traces of effects of 0.3 μmol·L−1 C1 on IKur before and after application,
and recovery after washout. (D) Current–voltage curve of the effect of the application of 0.3 μmol·L−1 C1 on IKur current, and after washout,
compared with control, n = 5 cells). *P < 0.05, significantly different from control values; paired Student’s t-test.
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activation by 504 ± 73%, whereas 1 μmol·L−1 of C1 inhibited
NFAT activation by approximately 50%. C1 also significantly
reduced AngII-induced activation of NFAT to 160 ± 23% of
control values (Figure 6C.).
Effects of C1 on ventricular myocyte
excitation–contraction coupling
A desirable property of potential compounds for AF is a
minimal effect on EC coupling in ventricular myocytes.
Single rat ventricular myocytes were field-stimulated at 1 Hz;
contractility and calcium transients were then measured
by edge detection and calcium imaging. Application of
3 μmol·L−1 C1 had no significant effect on (i) diastolic resting
cell length or calcium levels or (ii) peak systolic contractility
or calcium transient amplitude (Figure 7A,B).
The results presented in Figure 3 indicate that C1 inhibits
the late component of the cardiac voltage-gated sodium
channel current compared with peak current. Therefore, the
effects of C1 were tested in a single-ventricular myocyte
model of late sodium current-induced disturbances in
calcium homeostasis by pretreatment of myocytes with
3 nmol·L−1 ATX-II. ATX-II pretreatment results in markedly
elevated diastolic calcium levels and the loss of uniform
calcium transients (Figure 7C,E,F). In contrast, application of
C1 (1 μmol·L−1) significantly reduced the magnitude of ATX-
II-induced diastolic calcium elevations (C1 = 5.9 ± 2.9% vs.
control = 57.8 ± 5.9% of maximal transient amplitude, P <
0.01, n = 5 cells) and significantly delayed the onset of
calcium transient dysfunction (C1 = 5.3 ± 0.7 min vs 2.4 ±
0.4 min for control, P < 0.01, n = 10 cells, Figure 7D, E, F).
Effects of C1 in a model of inducible AF
in dogs
Right atrial effective refractory period (AERP) measurements
before the commencement of rapid atrial pacing at 400
beats·min−1 yielded values of 118 ± 3.7 and 130 ± 3.2 ms in
Figure 3
Effect of C1 on rat atrial IKACh currents. (A) Representative traces of the effects of 3 μmol·L−1 C1 on IKACh whole-cell currents induced by 10 μmol·L−1
carbachol. (B) Grouped data current–voltage curves of control, carbachol and carbachol + 3 μmol·L−1 C1 (n = 5 cells, currents normalized to
control values). *P < 0.05, #P < 0.01 significantly different from control values; paired Student’s t-test. (C) Concentration–inhibition curve of the
effect of C1 on IKACh current (n = 4–6 cells for each concentration).
BJP I Baczko et al.
98 British Journal of Pharmacology (2014) 171 92–106
Figure 4
Effect of C1 on Nav1.5 currents. 3 nmol·L−1 ATX-II was added to induce the late sodium current component where late current recordings
are indicated. (A) Representative traces of effects on Nav1.5 current with control, on application of 3 μmol·L−1 C1, and after washout.
(B) Current–voltage curves on application of 3 μmol·L−1 C1 and after washout, normalized to control values. (C) Representative traces of control
and the effect of application of 0.3, 1 and 3 μmol·L−1 C1. (D) Concentration–inhibition curve of the effect of C1 on peak and late Nav1.5 current
(late current IC50 = 1.1 μmol·L−1, peak current IC50 = 3.2 μmol·L−1, n = 4–7 cells for each concentration).
Figure 5
Effects of C1 on hERG currents. (A) Identification of hERG currents by inactivation at positive holding potential, tail currents and inhibition by
1 μmol·L−1 E-4031. (B) Representative traces before and after application of 30 μmol·L−1 C1. (C) Concentration–inhibition curve of the effect of
C1 on hERG peak and tail currents (peak current IC50 = 30 μmol·L−1, tail current IC50 = 25 μmol·L−1, n = 4–6 cells for each concentration).
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conscious dogs (n = 5; at basic cycle lengths of 150 and
300 ms respectively). Rapid right atrial pacing for 6–7 weeks
resulted in a significant decrease of right AERP, as AERP
decreased below 80 ms in all five animals, and were defined as
79 ms for the following reason: the lower adjustable limit for
S1–S2 intervals in the pacemakers available for this study was
80 ms, therefore the exact AERP after 7 weeks of rapid atrial
pacing and immediately before C1 administration could not
be determined (measured AERP values were less than 80 ms in
all dogs at both basic cycle lengths (BCLs) as an S1–S2 interval
of 80 ms still evoked a P wave), although statistical compari-
son of AERP values was not possible. AERP measurements
following C1 administration yielded 87.5 ± 2.50 ms at 150 ms
BCL in four animals (in one animal AERP was less than
80 ms) and 90 ± 3.16 ms at 300 ms BCL, respectively, follow-
ing 0.3 mg·kg−1 C1; and 90.0 ± 3.16 ms at 150 ms BCL, 100 ±
3.16 ms at 300 ms BCL, respectively, following 1 mg·kg−1 C1
(n = 5; with the exception of AERP measurement at 150 ms
BCL following 0.3 mg·kg−1 C1).
The incidence of AF was not influenced by administration
of C1 (86.4 ± 6.4% in control vs. 71.2 ± 15.7% and 66.4 ±
15.7% following 0.3 and 1 mg·kg−1 C1, respectively, both P >
0.05). However, as typical ECG recordings and grouped data
show, the total duration of AF was significantly reduced by
1 mg·kg−1 C1 administration (Figure 8B–D) and the average
duration of AF episodes was also significantly decreased by
1 mg·kg−1 C1 (Figure 8A–D). These results clearly demonstrate
in vivo efficacy of C1 against AF in conscious dogs. HPLC
analysis of blood plasma collected within 5 min of i.v. bolus
injection showed that we obtained concentration ranges of
0.32–0.79 and 0.7–3.0 μmol·L−1 for the 0.3 and 1 mg·kg−1
doses respectively.
None of the investigated doses exhibited any QT interval
prolonging effect in five conscious dogs, yielding 261.7 ±
9.37 ms in control vs. 260.9 ± 8.77 ms (P = 0.15) following
0.3 mg·kg−1 C1 and 257.3 ± 9.05 ms (P = 0.55) following
1 mg·kg−1 C1.
Discussion
Ionic effects of C1
As decreased atrial action potential refractory period contrib-
utes to the development of AF, the design of atrial-specific
repolarization-delaying drugs has received much recent
attention (Tamargo et al., 2009; Dobrev and Nattel, 2010).
Specifically, inhibition of the IKur/Kv1.5 repolarizing potas-
sium channel that is predominantly expressed in atria rather
than ventricle (Wang et al., 1993; Gaborit et al., 2007;
Tamargo et al., 2009) has emerged as an attractive therapeutic
target (Tamargo et al., 2009). Results generated in this study
on recombinant Kv1.5 and human atrial myocyte IKur currents
indicate that C1 is an effective inhibitor of this atrial-specific
ion channel. The calculated IC50 values for Kv1.5 channels are
in the 0.11–0.36 μmol·L−1 range for late and peak Kv1.5
current inhibition, which are 180- to 600-fold lower than
observed for the parent molecule, resveratrol (66 μmol·L−1).
Furthermore, these IC50 values are 10- to 30-fold lower than
those reported for the recently developed AF drug vernakal-
ant that is in clinical use in Europe (Camm et al., 2012).
Further analysis revealed that C1 is a more effective Kv1.5
channel inhibitor at a higher stimulatory frequency of 3 Hz
compared with 1 Hz, indicating that C1 may display
increased inhibitory efficacy in fibrillatory tissue. Therefore,
our results indicate that C1 has a favourable pharmacological
Figure 6
The antioxidant and NFAT-inhibitory effects of C1. (A) Antioxidant
capacity of C1 and resveratrol expressed as a fraction of control H2O2
fluorescence. (B) Grouped concentration NFAT-inhibition data for
C1. *P < 0.05, significantly different from control values; ANOVA. (C)
C1 significantly inhibits AngII-mediated NFAT activation in neonatal
rat ventricular myocytes. *P < 0.05, significantly different from
control values; ANOVA.
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and frequency-dependent inhibitory profile for Kv1.5 currents
that are both desirable properties for novel AF therapeutic
agents.
Recent research has suggested that inhibition of peak and
late atrial sodium currents may also be an attractive strategy
to suppress AF (Burashnikov et al., 2007; Burashnikov and
Antzelevitch, 2012). Inhibition of peak sodium current in a
frequency-dependent manner may reduce the occurrence of
premature action potentials and reduce the incidence of AF.
Whereas the induction of the Nav1.5 late current may not
only increase the risk of early after depolarization (EAD)-
induced arrhythmias but also lead to excessive sodium
loading within cells that may contribute to chronic calcium
loading that is considered to be a primary trigger for EADs
and calcineurin-mediated activation of the NFAT gene tran-
scriptional pathway that contributes to maladaptive hyper-
trophic remodelling observed in chronic AF (Lin et al., 2004).
Previous research from our group reported that the C1 parent
molecule resveratrol preferentially inhibited late over peak
Nav1.5 currents (Wallace et al., 2006; 26 μmol·L−1 vs.
77 μmol·L−1 respectively). Our results indicate that C1 inhib-
its the peak and late components of recombinant human
heart Nav1.5 currents more potently than resveratrol with
IC50s of 3.2 and 1.1 μmol·L−1 respectively. While we did not
directly compare atrial and ventricular sodium currents, these
findings warrant further investigation with respect to atrial-
specific sodium channel inhibition by C1. However, results
from ventricular myocytes indicate that C1 does not affect EC
coupling at concentrations in the low micromolar range. In
contrast, C1 was effective at reducing calcium-transient
abnormalities caused by late sodium current induction with
ATX-II. These findings suggest C1 will not interfere with
ventricular EC coupling at concentrations effective at inhib-
iting atrial Kv1.5 and peak/late sodium channel currents.
Inhibition of the hERG (Kv11.2) potassium channel is a
highly undesirable property of any new drug as significant
Figure 7
Effect of C1 on excitation–contraction coupling in rat ventricular myocytes. (A) Effect of 3 μmol·L−1 C1 on diastolic resting cell length and peak
systolic contractility. (B) Representative calcium transient recordings of the effect of 3 μmol·L−1 C1 on transient amplitude. (C) Effect of 3 nmol·L−1
ATX-II on diastolic calcium transient amplitude. (D) Effect of 1 μmol·L−1 C1 pretreatment on ATX-II-induced diastolic maximal calcium transient
amplitude. * P < 0.01, significantly different from control, n = 5 cells). (E) Column–graph representation of the effect of 1 μmol·L−1 C1 pretreatment
on ATX-II-induced diastolic maximal calcium transient amplitude. *P < 0.05, significantly different from control values; paired Student’s t-test (F)
Effect of 1 μmol·L−1 C1 on onset of ATX-II-induced calcium transient dysfunction (C1 = 5.5 ± 0.8 min, control 3.1 ± 0.4), *P < 0.05, significantly
different from control values; paired Student’s t-test n = 10 cells).
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hERG inhibition can lead to excessive action potential pro-
longation and life-threatening Torsades des Pointes arrhyth-
mias (Sanguinetti and Tristani-Firouzi, 2006). Accordingly, we
tested the effects of C1 on recombinant hERG channel whole-
cell currents and observed that C1 is a weak inhibitor of peak
and tail hERG currents with IC50 values of 30 and 25 μmol·L−1
respectively. These results indicate that C1 is unlikely to
exhibit any QT prolongation via hERG channel inhibition at
concentrations shown to be effective at inhibiting Kv1.5,
Nav1.5 and IKACh channels.
Figure 8
Effect of C1 administration on experimental atrial fibrillation (AF) in conscious dogs. (A) Representative ECG recording from a conscious dog
showing right atrial tachypacing at 400 min−1. (B) Representative ECG recording from a conscious dog exhibiting AF following right atrial
800 min−1 burst pacing (control). (C) Representative ECG recording from a conscious dog with a short duration of AF in response to right atrial
burst pacing following 1 mg·kg−1, i.v., C1 administration. Note P wave reoccurrence after cessation of AF on the magnified inset. (D) Grouped data
show that 1 mg·kg−1 C1 administration significantly reduced the total duration of atrial fibrillation and the average duration of AF episodes in
conscious dogs. *p < 0.05, **p < 0.01; significantly different from control values, one way ANOVA, n = 5 animals
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With respect to the overall inhibitory profile on ion chan-
nels tested in this study, C1 displays marked selectivity in the
following order of IC50 values Kv1.5 (late) < Kv1.5 (peak) <
Nav1.5 (late) < IKACh < Nav1.5 (peak) << hERG (tail) < hERG
(peak; Figure 9). These results are summarized in Figure 9 and
indicate that C1 displays a favourable ion channel inhibitory
profile that merits further characterization as a potential
treatment for AF.
Non-ionic effects of C1
The generation of ROS in the fibrillating atria is likely to
contribute to the disturbances in the ionic and non-ionic
milieu observed in AF (Carnes et al., 2001; Mihm et al., 2001).
Furthermore, Kv1.5 activity is increased in the presence of the
ROS H2O2 (Caouette et al., 2003). Resveratrol exhibits a
widely described antioxidant capacity that contributes to its
well-documented biological effects (Brisdelli et al., 2009;
Dolinsky and Dyck, 2011; Wu and Hsieh, 2011; Chung et al.,
2012). Our results show that C1 possesses an antioxidant
capacity similar to that of resveratrol. While the concentra-
tions of C1 required to yield significant quenching of H2O2
are higher than those exerting its Kv1.5 and Nav1.5 inhibitory
effects, C1 levels may accumulate in the plasma-membrane
as resveratrol is known to partition into lipid membranes
leading to significant tissue accumulation (Sale et al., 2004).
Furthermore, binding of C1 to Kv1.5 channels may addition-
ally contribute to inhibition of Kv1.5 currents in the presence
of ROS by decreasing the ROS-induced activation (Caouette
et al., 2003).
Activation of the NFAT transcription pathway is an
important signalling pathway that contributes to the initia-
tion of maladaptive hypertrophy and chronic AF (Cha et al.,
2004; Wilkins et al., 2004) and activation and nuclear trans-
location of NFAT is increased in AF (Lin et al., 2004). Our
previous research indicated that resveratrol inhibited NFAT
nuclear translocation and reduced phenylephrine-induced
hypertrophy in cardiac myocytes (Chan et al., 2008). Inter-
estingly, our present results also indicated that C1 inhibited
basal and angiotensin-II-induced NFAT activation at similar
concentrations (IC50 ∼ 1 μmol·L−1) to resveratrol. While this
effect may not play a major role in the reduction of AF in the
acute setting, it may become more important in the preven-
tion of transient AF conversion into chronic AF as the atria
becomes remodelled.
In vivo efficacy
To test the in vivo efficacy of C1, we used a model of AF in
chronically instrumented, conscious dogs, where electro-
physiological changes favouring the development of AF were
elicited by chronic rapid right atrial pacing (Figure 8A). Atrial
tachypacing in dogs is an established AF model leading to
electrical and structural remodelling (Morillo et al., 1995;
Gaspo et al., 1997). Atrial tachycardia and flutter have also
been shown to lead to similar atrial remodelling in humans
(Franz et al., 1997). Therefore, the significantly decreased
duration of AF (Figure 8B–D) and possibly the increased AERP
following C1 administration provides in vivo evidence that
C1 may be beneficial in the treatment of certain forms of AF
in patients.
Interestingly, treatment with C1 (0.3 and 1 mg·kg−1, i.v.)
did not reduce the incidence of burst-induced AF in this
study; however, it significantly reduced the duration of AF
episodes. Selective and non-selective IKur blocking compounds
have been shown to reduce both the incidence and the dura-
tion of AF (Ford and Milnes, 2008). However, one must con-
sider the electrical and structural remodelling of the atria
following chronic AF in patients and thtat following chronic
rapid atrial pacing in animal models (Nattel et al., 2007).
Remodelling can alter the efficacy and effective doses of com-
pounds developed for the treatment of AF. Although no
change in IKur density was previously observed in a tachy-
paced dog AF model (Yue et al., 1997), the down-regulation of
IKur has been demonstrated in humans with chronic AF (Van
Wagoner et al., 1997; Bosch et al., 1999; Caballero et al.,
2010). Such down-regulation of Kv1.5 currents in this model,
if present, might have influenced the in vivo effect of C1,
making the IKur current-blocking effect less important in this
particular model. Other compounds blocking IKur that we
recently investigated in our laboratory (unpublished data) in
the same model (with similar IC50 values for IKur) significantly
decreased the incidence of burst-induced AF in i.v. doses of
3 mg·kg−1 or higher. A recent review summarizing data on the
cardiac electrophysiological effects of novel IKur blockers also
found that they were effective against AF induction in i.v.
doses of 1–3 mg·kg−1 and higher (Ford and Milnes, 2008). In
the present study, due to limits in the synthesized amount of
C1 (required for several parallel in vitro studies), it was not
feasible to investigate C1 in vivo at a dose of 3 mg·kg−1.
Importantly, C1 did not prolong the QT interval in con-
scious dogs in the present study, suggesting that C1 is
unlikely to provoke ventricular arrhythmias based on repo-
larization disturbances. These latter findings support our
results on weak C1 hERG channel inhibition and a lack of
effect of C1 on EC coupling in single ventricular myocytes. As
this animal model represents AF in the setting of previously
remodelled atria leading to an increased induction of AF, the
pronounced acute effects observed with C1 are likely to be
Figure 9
Concentration–inhibition curves of the effects of C1 on Kv1.5, IKACh,
Nav1.5, and hERG currents. Kv1.5: Late current IC50 = 0.11 μmol·L−1,
peak current IC50 = 0.36 μmol·L−1. IKACh: IC50 = 1.9 μmol·L−1. Nav1.5:
Late current IC50 = 1.1 μmol·L−1, peak current IC50 = 3.2 μmol·L−1.
hERG: Tail current IC50 = 25 μmol·L−1, peak current IC50 =
30 μmol·L−1. Data replotted from Figures 1–5.
BJPNovel small molecule for atrial fibrillation
British Journal of Pharmacology (2014) 171 92–106 103
mediated by its ion channel inhibitory and antioxidant prop-
erties rather than inhibition of NFAT activation. Whether
chronic treatment with C1 reduces maladaptive remodelling
remains to be determined by long-term studies.
Limitations of the study
While the effects of C1 on human atrial cell IKur were meas-
ured, the effects of C1 on human atrial cell action potentials
were not studied due to the limited supply of atrial append-
age tissue and the limited number of viable cells following
enzymic digestion. For practical reasons, all ionic currents
were measured at room temperature (20–22°C) rather than at
37°C. Moreover, we acknowledge that the cardiac rhythm
status of the donor could influence the electrophysiological
response to C1 in human atrial cells; however, no informa-
tion was available on the cardiac rhythm status of the
patients whose atrial tissue samples were used in this study. In
the conscious dog model of AF, the AERP could not be meas-
ured below 80 ms as this is the shortest S1–S2 duration that
can be set in the human pacemakers used in this study. The
conscious animal experimental set-up did not allow us to
directly measure AERP as that would have required anaesthe-
sia and thoracotomy. Therefore, the exact statistical evalua-
tion of the possible AERP-prolonging effect of C1 was not
performed in this study.
In conclusion, the aetiology of AF is complex, and a
number of ionic and non-ionic pathways contribute to the
initiation andmaintenance of AF (Franz et al., 1997; Lin et al.,
2004). Therefore, inhibition of more than one of these path-
ways is likely to provide greater anti-fibrillatory efficacy than
one pathway alone (Ehrlich and Nattel, 2009; Dobrev and
Nattel, 2010; Dobrev et al., 2012). Our results indicate that
the resveratrol derivative C1 is an effective inhibitor of several
potential targets involved in AF development and confirmed
that C1 is also effective at reducing the duration of AF epi-
sodes in a model of inducible AF in dogs.
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